104
Participants
Start Date
October 19, 2009
Primary Completion Date
September 5, 2017
Study Completion Date
September 5, 2017
lenalidomide
"Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~* Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity"
Long Island Jewish Medical Center CLL Research and Treatment Program, New Hyde Park
Institut Paoli Calmettes, Marseille
Charite -Universitätsmedizin Berlin, Berlin
Karolinska Universitetssjukhuset, Stockholm
Roswell Park Cancer Institute, Buffalo
Azienda Ospedaliera Universitaria San Martino, Genova
Ernst-Moritz-Arndt-Universität Greifswald, Greifswald
Drexel University, College of Medicine, Clinical Research Group, Philadelphia
I.R.C.C.S. Ospedale San Raffaele, Milan
Istituto Europeo di Oncologia - IEO, Milan
Universitatsklinikum Schleswig Holstein, Kiel
Wake Forest University School of Medicine, Winston-Salem
CHRU - Hopital du Haut Leveque, Pessac
CHU Montpellier - Hôpital Saint Eloi, Montpellier
Cancer and Blood Disease Center, Lecanto
CHU Rennes Hematology, Rennes
Universita degli Studi di Padova, Padua
CHU Grenoble, Grenoble
Cleveland Clinic Foundation, Cleveland
Gabrail Cancer Center Research, Canton
Universitatsklinikum Essen, Essen
Karmanos Cancer Institute, Detroit
Klinikum der Universitat zu Koln, Cologne
Hopital Robert Debre, Reims
CHRU Hopital Brabois, Vandœuvre-lès-Nancy
Rush University Medical Center, Chicago
CH Perpignan - Hopital Saint-Jean, Perpignan
Hopital Emile Muller, Mulhouse
Centre Hospitalier Lyon Sud, Pierre-Bénite
Clinique Victor Hugo, Le Mans
"Ematologia ed Immunologia, Azienda Ospedaliera Vito Fazzi di Lecce", Lecce
Hopital Pitie Salpetriere, Paris
CHU Sud, Amiens
University of Ulm Abteilung Innere Medizin III, Ulm
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage
Hopital Avicenne, Bobigny
UCSD Moores Cancer Center, La Jolla
Stanford University School of Medicine, Stanford
Cancer Center of Central Connecticut, Southington
Northwestern University Medical Center Division of Hematology Oncology, Chicago
Indiana University Cancer Center, Indianapolis
Hackensack University Medical Center, Hackensack
Cross Cancer Institute, Edmonton
Juravinski Cancer Centre, Hamilton
Universita' Degli Studi Di Perugia, Perugia
Hospital Clinic Provincial de Barcelona, Barcelona
Hospital Universitari Germans Trias i Pujol, Barcelona
St James's Institute of Oncology, Leeds
St.Bartholomew's Hospital, London
King's College Hospital, London
The Royal Marsden Hospital, London
Christie Hospital NHS Foundation Trust, Manchester
Lead Sponsor
Celgene
INDUSTRY